News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Daily News AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review Todd Neale July 24, 2025
News Daily News Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050 Todd Neale July 16, 2025
News Conference News ACC 2024 Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT Todd Neale March 27, 2024
News Daily News AEGIS-II Misses Primary Endpoint, Dealing New Blow to HDL Hypothesis Todd Neale February 14, 2024
News Daily News Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People Todd Neale November 22, 2023
News Conference News AHA 2023 Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV Todd Neale November 17, 2023
News Daily News Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA Todd Neale September 19, 2023
News Conference News ACC 2023 Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study Todd Neale March 10, 2023
News Daily News PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial Todd Neale January 18, 2023
News Daily News Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy Todd Neale July 20, 2022
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2020 OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients Todd Neale November 15, 2020
News Conference News AHA 2020 Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT Todd Neale November 15, 2020
News Conference News TCT 2020 Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT Todd Neale October 21, 2020